Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma

Alissa A. Thomas, Lauren E. Abrey, Robert Terziev, Jeffrey Raizer, Nina L. Martinez, Peter Forsyth, Nina Paleologos, Matthew Matasar, Craig S. Sauter, Craig Moskowitz, Stephen D Nimer, Lisa M. Deangelis, Thomas Kaley, Sean Grimm, David N. Louis, J. Gregory Cairncross, Katherine S. Panageas, Samuel Briggs, Geraldine Faivre, Nimish A. MohileJayesh Mehta, Philip Jonsson, Debyani Chakravarty, Jianjiong Gao, Nikolaus Schultz, Cameron W. Brennan, Jason T. Huse, Antonio Omuro

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background. Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Methods. Patients with AO/AOA received 6 cycles of TMZ (200 mg/m2 × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m2/day

Original languageEnglish (US)
Pages (from-to)1380-1390
Number of pages11
JournalNeuro-Oncology
Volume19
Issue number10
DOIs
StatePublished - Oct 1 2017
Externally publishedYes

Fingerprint

temozolomide
Oligodendroglioma
Stem Cells
Transplants
Drug Therapy
Thiotepa
Chemoradiotherapy
Radiotherapy
Survival
Neoplasms

Keywords

  • 1p/19q codeletion
  • Anaplastic oligodendroglioma
  • Autologous stem cell transplant
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. / Thomas, Alissa A.; Abrey, Lauren E.; Terziev, Robert; Raizer, Jeffrey; Martinez, Nina L.; Forsyth, Peter; Paleologos, Nina; Matasar, Matthew; Sauter, Craig S.; Moskowitz, Craig; Nimer, Stephen D; Deangelis, Lisa M.; Kaley, Thomas; Grimm, Sean; Louis, David N.; Cairncross, J. Gregory; Panageas, Katherine S.; Briggs, Samuel; Faivre, Geraldine; Mohile, Nimish A.; Mehta, Jayesh; Jonsson, Philip; Chakravarty, Debyani; Gao, Jianjiong; Schultz, Nikolaus; Brennan, Cameron W.; Huse, Jason T.; Omuro, Antonio.

In: Neuro-Oncology, Vol. 19, No. 10, 01.10.2017, p. 1380-1390.

Research output: Contribution to journalArticle

Thomas, AA, Abrey, LE, Terziev, R, Raizer, J, Martinez, NL, Forsyth, P, Paleologos, N, Matasar, M, Sauter, CS, Moskowitz, C, Nimer, SD, Deangelis, LM, Kaley, T, Grimm, S, Louis, DN, Cairncross, JG, Panageas, KS, Briggs, S, Faivre, G, Mohile, NA, Mehta, J, Jonsson, P, Chakravarty, D, Gao, J, Schultz, N, Brennan, CW, Huse, JT & Omuro, A 2017, 'Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma', Neuro-Oncology, vol. 19, no. 10, pp. 1380-1390. https://doi.org/10.1093/neuonc/nox086
Thomas, Alissa A. ; Abrey, Lauren E. ; Terziev, Robert ; Raizer, Jeffrey ; Martinez, Nina L. ; Forsyth, Peter ; Paleologos, Nina ; Matasar, Matthew ; Sauter, Craig S. ; Moskowitz, Craig ; Nimer, Stephen D ; Deangelis, Lisa M. ; Kaley, Thomas ; Grimm, Sean ; Louis, David N. ; Cairncross, J. Gregory ; Panageas, Katherine S. ; Briggs, Samuel ; Faivre, Geraldine ; Mohile, Nimish A. ; Mehta, Jayesh ; Jonsson, Philip ; Chakravarty, Debyani ; Gao, Jianjiong ; Schultz, Nikolaus ; Brennan, Cameron W. ; Huse, Jason T. ; Omuro, Antonio. / Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. In: Neuro-Oncology. 2017 ; Vol. 19, No. 10. pp. 1380-1390.
@article{0e6d22f69bad4465afde3aedfa1b5521,
title = "Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma",
abstract = "Background. Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Methods. Patients with AO/AOA received 6 cycles of TMZ (200 mg/m2 × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m2/day",
keywords = "1p/19q codeletion, Anaplastic oligodendroglioma, Autologous stem cell transplant, Temozolomide",
author = "Thomas, {Alissa A.} and Abrey, {Lauren E.} and Robert Terziev and Jeffrey Raizer and Martinez, {Nina L.} and Peter Forsyth and Nina Paleologos and Matthew Matasar and Sauter, {Craig S.} and Craig Moskowitz and Nimer, {Stephen D} and Deangelis, {Lisa M.} and Thomas Kaley and Sean Grimm and Louis, {David N.} and Cairncross, {J. Gregory} and Panageas, {Katherine S.} and Samuel Briggs and Geraldine Faivre and Mohile, {Nimish A.} and Jayesh Mehta and Philip Jonsson and Debyani Chakravarty and Jianjiong Gao and Nikolaus Schultz and Brennan, {Cameron W.} and Huse, {Jason T.} and Antonio Omuro",
year = "2017",
month = "10",
day = "1",
doi = "10.1093/neuonc/nox086",
language = "English (US)",
volume = "19",
pages = "1380--1390",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma

AU - Thomas, Alissa A.

AU - Abrey, Lauren E.

AU - Terziev, Robert

AU - Raizer, Jeffrey

AU - Martinez, Nina L.

AU - Forsyth, Peter

AU - Paleologos, Nina

AU - Matasar, Matthew

AU - Sauter, Craig S.

AU - Moskowitz, Craig

AU - Nimer, Stephen D

AU - Deangelis, Lisa M.

AU - Kaley, Thomas

AU - Grimm, Sean

AU - Louis, David N.

AU - Cairncross, J. Gregory

AU - Panageas, Katherine S.

AU - Briggs, Samuel

AU - Faivre, Geraldine

AU - Mohile, Nimish A.

AU - Mehta, Jayesh

AU - Jonsson, Philip

AU - Chakravarty, Debyani

AU - Gao, Jianjiong

AU - Schultz, Nikolaus

AU - Brennan, Cameron W.

AU - Huse, Jason T.

AU - Omuro, Antonio

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background. Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Methods. Patients with AO/AOA received 6 cycles of TMZ (200 mg/m2 × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m2/day

AB - Background. Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Methods. Patients with AO/AOA received 6 cycles of TMZ (200 mg/m2 × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m2/day

KW - 1p/19q codeletion

KW - Anaplastic oligodendroglioma

KW - Autologous stem cell transplant

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=85030786842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030786842&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nox086

DO - 10.1093/neuonc/nox086

M3 - Article

C2 - 28472509

AN - SCOPUS:85030786842

VL - 19

SP - 1380

EP - 1390

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 10

ER -